UKM-PS-III: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 21, 2026 - P3 | N=422 | Completed | Sponsor: AO GENERIUM | Active, not recruiting ➔ Completed
Trial completion • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis
|